3CL Protease Inhibitor Composition for COVID-19 Viral Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective treatments to inhibit SARS-CoV-2 viral replication and treat COVID-19, given the global pandemic and the emergence of more aggressive L-type variants, and existing methods do not adequately target the 3CL protease of the virus.
Innovation Solution
Administering therapeutically effective amounts of specific SARS-CoV-2-related 3C-like protease inhibitors, such as (3S)-3-({N-[(4-methoxy-1H-indol-2-yl)carbonyl]-L-leucyl}amino)-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl derivatives, to inhibit viral replication and treat COVID-19.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatment methods are used, then treatment availability is maintained, but viral replication inhibition effectiveness is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of protease inhibitors to specifically target the 3CL protease of SARS-CoV-2. The invention introduces specific molecular features (such as the N-[(4-methoxy-1H-indol-2-yl)carbonyl]-L-leucyl amino group and 2-oxo-4-oxopyrrolidin-3-ylbutyl side chain) that change the binding parameters to achieve high-affinity inhibition of viral replication while maintaining therapeutic safety.
2Reliability
If targeted protease inhibition is implemented, then viral replication is effectively inhibited, but treatment complexity increases
Solution Approach 1:
The patent extracts and targets a specific critical component - the 3CL protease enzyme - that is essential for viral replication. By identifying and inhibiting this specific protease with highly selective compounds, the treatment focuses on the key viral mechanism without requiring complex multi-target approaches, thereby reducing overall treatment complexity while maintaining high effectiveness.
3Ease of operation
If multiple administration routes are provided, then patient accessibility is improved, but formulation complexity increases
Solution Approach 1:
The patent applies universality by developing a multi-functional treatment approach where the same core inhibitor compound can be administered through multiple routes (oral, inhalation, intranasal). The compound is designed with properties that allow it to be effectively delivered via different pathways, providing patient accessibility benefits without requiring entirely different treatment formulations for each route.
Data Source
AI summary
The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof. The invention also relates to inhibiting SARS-CoV-2 coronavirus viral replication activity comprising contacting SARS-CoV-2-related coronavirus protease with a therapeutically effective amount of a SARS-Cov-2 protease inhibitor, such as a SARS-Cov-2 3CL protease inhibitor and compositions comprising the same.